EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

INBRX-120, a CD8α-targeted detuned IL-2 that selectively expands and activates tumoricidal effector cells for safe and durable in vivo responses

Florian J Sulzmaier iD, Nadja Kern, Sae Jeong Ahn, Anya Polovina, Jason Ho, Abrahim Hussain, Garrett Cyprus, Chelsie Macedo, Rajay Pandit, William Crago, Emily Rowell, John C Timmer und 1 weitere

Journal for ImmunoTherapy of Cancer · 2023

DOI: 10.1136/jitc-2022-006116 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2023. Verfasst von Florian J Sulzmaier und 12 weiteren Autor:innen. Beteiligte Einrichtung: Inhibrx Inc, La Jolla, California, USA florian@inhibrx.com. Hauptthemen laut MEDLINE: Interleukin-2, Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Inhibrx Inc., San Diego, CA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

As a major driver of lymphocyte proliferation and activation interleukin 2 (IL-2) is a crucial mediator for antitumor responses. Despite promising activity in a subset of patients, wider therapeutic utility of IL-2 (aldesleukin) has been hampered by severe dose-limiting toxicities, the expansion of immunosuppressive regulatory T cells and a poor pharmacokinetic (PK) profile. Recent engineering efforts, including non-α IL-2 variants, have lowered the toxicity profile, but have yet to induce meaningful antitumor activity in a wider patient population.

Methods

We engineered INBRX-120, a CD8α-targeted Cisleukin™ molecule consisting of an affinity tuned IL-2 (IL2-x) connected to two high affinity CD8α-specific single domain antibodies via an effector-silenced Fc domain. To show that this large affinity differential enables directed IL-2 cis-signaling exclusively on CD8α-expressing tumoricidal effector cell populations, INBRX-120 effects on target cell expansion, activation and antitumor activity were tested in vitro. In vivo antitumor efficacy was evaluated in syngeneic mouse models alone or in combination with programmed cell death protein-1 (PD-1) blockade. Preclinical safety, as well as pharmacodynamic (PD) and PK profiling was carried out in non-human primates.

Results

INBRX-120 effectively expanded and enhanced the cytotoxic capacity of CD8 T cells and natural killer cells towards tumor cells without affecting regulatory T cells in vitro and in vivo. In syngeneic mouse models, INBRX-120 surrogate showed safe, potent, and durable antitumor efficacy alone and in combination with PD-1 blockade. In non-human primates, INBRX-120 expanded and activated CD8α-expressing effector cells, showed a favorable PK profile, and was well tolerated up to a dose of 1 mg/kg.

Conclusions

Through its unique cis-signaling activity on CD8α-expressing effector cells, INBRX-120 overcomes the major limitations of IL-2-based therapy and effectively harnesses IL-2’s potent intrinsic antitumor activity. This novel therapeutic strategy promises safer clinical activity that could induce meaningful antitumor efficacy in a wider set of patients with various cancer indications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interleukin-2NeoplasmsAnimalsMiceHumansProgrammed Cell Death 1 ReceptorCytotoxicity, ImmunologicCD8-Positive T-Lymphocytes

Stichwörter der Autor:innen

CytokinesCytotoxicity, ImmunologicImmunotherapyLymphocyte ActivationT-Lymphocytes

Substanzen

Interleukin-2Programmed Cell Death 1 Receptor

Autor:innen und Institutionen

  • Inhibrx Inc, La Jolla, California, USA florian@inhibrx.com.
  • Inhibrx Inc, La Jolla, California, USA.

ORCID-Profile: Florian J Sulzmaier

Förderung

  • Inhibrx Inc., San Diego, CA

Zitieren

APA

Sulzmaier, F. J., Kern, N., Ahn, S. J., Polovina, A., Ho, J., Hussain, A., Cyprus, G., Macedo, C., Pandit, R., Crago, W., Rowell, E., Timmer, J. C., & Eckelman, B. P. (2023). INBRX-120, a CD8α-targeted detuned IL-2 that selectively expands and activates tumoricidal effector cells for safe and durable in vivo responses. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2022-006116

Vancouver

Sulzmaier FJ, Kern N, Ahn SJ, Polovina A, Ho J, Hussain A, et al. INBRX-120, a CD8α-targeted detuned IL-2 that selectively expands and activates tumoricidal effector cells for safe and durable in vivo responses. Journal for ImmunoTherapy of Cancer. 2023. doi:10.1136/jitc-2022-006116

BibTeX
@article{Sulzmaier2023,
  author = {Sulzmaier, Florian J and Kern, Nadja and Ahn, Sae Jeong and Polovina, Anya and Ho, Jason and Hussain, Abrahim and Cyprus, Garrett and Macedo, Chelsie and Pandit, Rajay and Crago, William and Rowell, Emily and Timmer, John C and Eckelman, Brendan P},
  title = {INBRX-120, a CD8α-targeted detuned IL-2 that selectively expands and activates tumoricidal effector cells for safe and durable in vivo responses},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2023},
  doi = {10.1136/jitc-2022-006116}
}
Kostenlos starten →